Use of bivalirudin as the foundation anticoagulant during percutaneous peripheral interventions

Journal of Invasive Cardiology

Volumn 18, Issue 3, 2006, Pages 125-128

  Eres, Avichai ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HIRULOG; THROMBIN INHIBITOR;

AGED; ANTICOAGULANT THERAPY; ARTERY DISEASE; ARTERY OCCLUSION; ARTICLE; BLEEDING; CAUSE OF DEATH; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; FEMORAL ARTERY; HEART INFARCTION; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; ILIAC ARTERY; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PERCUTENOUS PERIPHERAL INTERVETION; PERIPHERAL VASCULAR DISEASE; RETROSPECTIVE STUDY; REVASCULARIZATION; TREATMENT DURATION;

AGED; ANGIOPLASTY; ANTICOAGULANTS; ANTITHROMBINS; ARTERIAL OCCLUSIVE DISEASES; FEASIBILITY STUDIES; FEMALE; HEMORRHAGE; HIRUDINS; HUMANS; INCIDENCE; ISCHEMIA; MALE; MEDICAL RECORDS; MIDDLE AGED; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY PLASMINOGEN ACTIVATOR;

EID: 33645857971     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Shammas NW, Lemke JH, Dippel EJ, et al. In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant. J Invasive Cardiol 2003;15:242-246.
2. Bittl JA, Chaitman BR, Feit, F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the bivalirudin angioplasty study. Am Heart J 2001;142:952-959.
3. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 Trial). Am J Cardiol 2004;93:1092-1096.
4. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 Randomized Trial. JAMA 2003;289:853-863.
5. Allie DE, Lirtzman MD, Wyatt CH, et al. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: A safe and feasible alternative for renal and iliac interventions. J Invasive Cardiol 2003;15:334-342.
6. Lacoste L, Lan JYT, Hung J, et al. Hyperlipidemia and coronary disease. Circulation 1995;92:3172-3177.
7. Tsang J, Sheppard R, Mak KH, et al. Six-month outcomes of percutaneous transluminal coronary angioplasty in hypertensive patients: Results for the ROSETTA registry. Am Heart J 2002;143:124-129.
8. Samama CM, Thiry D, Elalamy I, et al. Perioperative activation of hemostasis in vascular surgery patients. Anesthesiology 2001;94:74-78.
9. Lowe GD, Reid AW, Leiberman DP. Management of thrombosis in peripheral arterial disease. Br Med Bull 1994;50:923-935.
10. Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000;12:27F-32F.
11. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995;74:1-6.
12. Mann KG, Butenas S, and Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003;23:17-25.
13. Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574.
14. Schneider DJ, Tracy PB, Mann KG, et al. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation 1997;96:2877-2883.
15. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low molecular weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 2001;119:64S-94S.
16. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary intervention: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002;143:847-853.
17. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993;69:157-163.
18. Grubbs G. Anticoagulation in peripheral interventions. Endovascular Today 2003;1-4.
19. Shammas NW, Lemke JH, Dippel EJ, et al. Bivalirudin in peripheral vascular interventions: A single center experience. J Invasive Cardiol 2003;15:401-404.
20. Allie DE, Hall P, Shammas NW, et al. The Angiomax Peripheral Procedure Registry of Vascular Events trial (APPROVE): Inhospital and 30-day results. J Invasive Cardiol 2004;16:651-656.
21. Chew DP, Bhatt DL, Kimball W, et al. Bivalirudin provides increasing benefit with decreasing renal function: A meta-analysis of randomized trials. Am J Cardiol 2003;93:919-923.